{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-25-095628","form_type":"8-K","ticker":"KYNB","cik":"0000921299","company_name":"KYNTRA BIO, INC.","filed_at":"2025-07-14T23:59:59+00:00","discovered_at":"2026-05-14T18:02:46.707517+00:00","generated_at":"2026-05-18T06:50:34.622743+00:00","sec_items":["1.01","9.01"],"event_type":"debt","sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"confidence":"high","headline":"FibroGen reduces minimum cash covenant to $18.75M in third amendment to Morgan Stanley financing","bullets":["Third Amendment to Financing Agreement dated July 14, 2025 lowers required U.S. qualified cash from $22.5M to $18.75M.","Amendment with lenders managed by Morgan Stanley Tactical Value and agent Wilmington Trust.","Effective July 14, 2025; no other changes to Financing Agreement terms."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-25-095628","json":"https://secwatch.observer/filing/0000950170-25-095628.json","markdown":"https://secwatch.observer/filing/0000950170-25-095628.md","text":"https://secwatch.observer/filing/0000950170-25-095628.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/921299/000095017025095628/0000950170-25-095628-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/921299/000095017025095628/fgen-20250714.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-18T06:50:34.622743+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}